Efficacy and Safety Evaluation of a Regimen Consisting of Peginterferon Lambda-1a + Ribavirin + Daclatasvir (Lambda + RBV + DCV) in HCV Genotype 1b Treatment naïve Patients or Prior Relapsers to Peginterferon Alfa + Ribavirin (Alfa + RBV) Therapy

PHASE3CompletedINTERVENTIONAL
Enrollment

444

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

October 31, 2014

Study Completion Date

October 31, 2014

Conditions
Hepatitis C
Interventions
BIOLOGICAL

Peginterferon Lambda-1a

BIOLOGICAL

Peginterferon Alfa-2a

DRUG

Ribavirin

DRUG

Daclatasvir

DRUG

Telaprevir

Trial Locations (78)

100

Local Institution, Taipei

112

Local Institution, Taipei

333

Local Institution, Taoyuan District

404

Local Institution, Taichung

704

Local Institution, Tainan City

1119

Local Institution, Buenos Aires

1221

Local Institution, Buenos Aires

2000

Local Institution, Prov de Santa Fe

10021

Weill Cornell Medical College, New York

12601

Premier Medical Group Of The Hudson Valley, Pc, Poughkeepsie

13110

Local Institution, Zafed

13353

Local Institution, Berlin

18102

Lehigh Valley Health Network, Allentown

20099

Local Institution, Hamburg

27100

Local Institution, Pavia

28029

Local Institution, Madrid

30060

Gastrointestinal Specialists Of Georgia Pc, Marietta

34362

Local Institution, Haifa

37205

Nashville Medical Research Institute, Nashville

38043

Local Institution, Grenoble

39008

Local Institution, Santander

41100

Local Institution, Modena

45122

Local Institution, Essen

50009

Local Institution, Zaragoza

52621

Local Institution, Tel Litwinsky

56124

Local Institution, Pisa

64239

Local Institution, Tel Aviv

68167

Local Institution, Mannheim

71100

Local Institution, Foggia

76012

Texas Clinical Research Institute, Llc, Arlington

77030

Medvamc, Houston

80756

Local Institution, Kaohsiung

81377

Local Institution, München

90822

Va Long Beach Healthcare System, Long Beach

92118

Local Institution, Clichy

94804

Local Institution, Villejuif

98125

Local Institution, Messina

111123

Local Institution, Moscow

119991

Local Institution, Moscow

119992

Local Institution, Moscow

121170

Local Institution, Moscow

125367

Local Institution, Moscow

191167

Local Institution, Saint Petersburg

196645

Local Institution, Saint Petersburg

355017

Local Institution, Stavropol

1058470

Local Institution, Minato-ku

1308575

Local Institution, Sumida-ku

1808610

Local Institution, Musashino-shi

2138587

Local Institution, Kawasaki-shi

2320024

Local Institution, Yokohama

2458575

Local Institution, Yokohama

3313193

Local Institution, Higashiibaraki-gun

4678602

Local Institution, Nagoya

5008727

Local Institution, Gifu

6028566

Local Institution, Kyoto

6128555

Local Institution, Kyoto

6468558

Local Institution, Tanabe-shi

6500047

Local Institution, Kobe

7348511

Local Institution, Hiroshima

8028533

Local Institution, Kitakyushu-shi

8030816

Local Institution, Kitakyushu

8408571

Local Institution, Saga

8628655

Local Institution, Kumamoto

C1181

Local Institution, Buenos Aires

C1405BCK

Local Institution, Capital Federal

B7600FZN

Local Institution, Mar del Plata

0600033

Local Institution, Sapporo

15-540

Local Institution, Bialystok

91-347

Local Institution, Lodz

41-400

Local Institution, Mysłowice

50-349

Local Institution, Wroclaw

614-735

Local Institution, Busan

110-774

Local Institution, Seoul

135-720

Local Institution, Seoul

138-736

Local Institution, Seoul

143-729

Local Institution, Seoul

08916

Local Institution, Barcelona

SE5 9RS

Local Institution, London

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT01718158 - Efficacy and Safety Evaluation of a Regimen Consisting of Peginterferon Lambda-1a + Ribavirin + Daclatasvir (Lambda + RBV + DCV) in HCV Genotype 1b Treatment naïve Patients or Prior Relapsers to Peginterferon Alfa + Ribavirin (Alfa + RBV) Therapy | Biotech Hunter | Biotech Hunter